CA1213544A - Procede de production de facteur de lyse de cellules cibles et utilisation - Google Patents

Procede de production de facteur de lyse de cellules cibles et utilisation

Info

Publication number: CA1213544A
Authority: CA; Canada
Prior art keywords: human; tclf; cell line; htnf; animal
Prior art date: 1981-07-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000408532A

Other languages

English (en)

Inventor

Masakazu Mitsuhashi

Haruo Ohnishi

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hayashibara Seibutsu Kagaku Kenkyujo KK

Mochida Pharmaceutical Co Ltd

Original Assignee

Hayashibara Seibutsu Kagaku Kenkyujo KK

Mochida Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1981-07-31

Filing date

1982-07-30

Publication date

1986-11-04

1981-07-31 Priority claimed from JP56120459A external-priority patent/JPS5821621A/ja

1981-11-21 Priority claimed from JP56187626A external-priority patent/JPS5889195A/ja

1981-11-21 Priority claimed from JP56187627A external-priority patent/JPH0764744B2/ja

1981-12-21 Priority claimed from JP56205115A external-priority patent/JPS6011890B2/ja

1982-07-30 Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK, Mochida Pharmaceutical Co Ltd filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK

1986-11-04 Application granted granted Critical

1986-11-04 Publication of CA1213544A publication Critical patent/CA1213544A/fr

Status Expired legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 61
230000006037 cell lysis Effects 0.000 title claims abstract description 6
210000005260 human cell Anatomy 0.000 claims abstract description 95
210000004027 cell Anatomy 0.000 claims abstract description 92
241001465754 Metazoa Species 0.000 claims abstract description 87
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims abstract description 71
102100040247 Tumor necrosis factor Human genes 0.000 claims abstract description 44
239000000411 inducer Substances 0.000 claims abstract description 44
235000015097 nutrients Nutrition 0.000 claims abstract description 30
102000057041 human TNF Human genes 0.000 claims abstract description 27
210000001124 body fluid Anatomy 0.000 claims abstract description 20
239000010839 body fluid Substances 0.000 claims abstract description 20
238000009792 diffusion process Methods 0.000 claims abstract description 14
238000009825 accumulation Methods 0.000 claims abstract description 13
238000007864 suspending Methods 0.000 claims abstract description 9
241000021559 Dicerandra Species 0.000 claims abstract description 7
235000010654 Melissa officinalis Nutrition 0.000 claims abstract description 7
239000000865 liniment Substances 0.000 claims abstract description 7
238000012258 culturing Methods 0.000 claims abstract description 5
102000016605 B-Cell Activating Factor Human genes 0.000 claims abstract 4
108010028006 B-Cell Activating Factor Proteins 0.000 claims abstract 4
102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 60
108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 60
239000000203 mixture Substances 0.000 claims description 40
206010028980 Neoplasm Diseases 0.000 claims description 24
238000000338 in vitro Methods 0.000 claims description 24
230000035508 accumulation Effects 0.000 claims description 11
108010062580 Concanavalin A Proteins 0.000 claims description 9
239000002158 endotoxin Substances 0.000 claims description 8
239000000126 substance Substances 0.000 claims description 7
241000700605 Viruses Species 0.000 claims description 6
238000003306 harvesting Methods 0.000 claims description 6
239000003226 mitogen Substances 0.000 claims description 6
102000003886 Glycoproteins Human genes 0.000 claims description 5
108090000288 Glycoproteins Proteins 0.000 claims description 5
108020004707 nucleic acids Proteins 0.000 claims description 5
102000039446 nucleic acids Human genes 0.000 claims description 5
150000007523 nucleic acids Chemical class 0.000 claims description 5
239000002773 nucleotide Substances 0.000 claims description 4
125000003729 nucleotide group Chemical group 0.000 claims description 4
150000001720 carbohydrates Chemical class 0.000 claims description 3
108090001090 Lectins Proteins 0.000 claims 3
102000004856 Lectins Human genes 0.000 claims 3
108010047620 Phytohemagglutinins Proteins 0.000 claims 3
239000001963 growth medium Substances 0.000 claims 3
239000002523 lectin Substances 0.000 claims 3
230000001885 phytohemagglutinin Effects 0.000 claims 3
201000011510 cancer Diseases 0.000 abstract description 9
239000000047 product Substances 0.000 description 29
238000004519 manufacturing process Methods 0.000 description 28
239000006285 cell suspension Substances 0.000 description 23
230000000694 effects Effects 0.000 description 23
239000000843 powder Substances 0.000 description 22
239000002504 physiological saline solution Substances 0.000 description 18
241000711408 Murine respirovirus Species 0.000 description 17
239000007924 injection Substances 0.000 description 16
238000002347 injection Methods 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 15
238000002360 preparation method Methods 0.000 description 15
241000699800 Cricetinae Species 0.000 description 12
230000035931 haemagglutination Effects 0.000 description 12
230000036046 immunoreaction Effects 0.000 description 11
239000012528 membrane Substances 0.000 description 11
239000000243 solution Substances 0.000 description 11
235000013601 eggs Nutrition 0.000 description 10
239000012737 fresh medium Substances 0.000 description 10
210000004881 tumor cell Anatomy 0.000 description 10
238000002474 experimental method Methods 0.000 description 9
241000699670 Mus sp. Species 0.000 description 8
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 8
230000009089 cytolysis Effects 0.000 description 8
239000003814 drug Substances 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
239000002674 ointment Substances 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
238000002054 transplantation Methods 0.000 description 8
206010003445 Ascites Diseases 0.000 description 7
206010006187 Breast cancer Diseases 0.000 description 7
208000026310 Breast neoplasm Diseases 0.000 description 7
206010057248 Cell death Diseases 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000012141 concentrate Substances 0.000 description 6
235000008504 concentrate Nutrition 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
230000003203 everyday effect Effects 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
238000011534 incubation Methods 0.000 description 6
238000011580 nude mouse model Methods 0.000 description 6
239000003826 tablet Substances 0.000 description 6
229940124597 therapeutic agent Drugs 0.000 description 6
230000006433 tumor necrosis factor production Effects 0.000 description 6
206010058467 Lung neoplasm malignant Diseases 0.000 description 5
239000012980 RPMI-1640 medium Substances 0.000 description 5
210000003719 b-lymphocyte Anatomy 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
230000006698 induction Effects 0.000 description 5
201000005296 lung carcinoma Diseases 0.000 description 5
239000002609 medium Substances 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
230000004083 survival effect Effects 0.000 description 5
239000000725 suspension Substances 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
241000711404 Avian avulavirus 1 Species 0.000 description 4
208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 4
206010073069 Hepatic cancer Diseases 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
210000001142 back Anatomy 0.000 description 4
239000000470 constituent Substances 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
239000012153 distilled water Substances 0.000 description 4
239000002662 enteric coated tablet Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
206010073071 hepatocellular carcinoma Diseases 0.000 description 4
150000002500 ions Chemical class 0.000 description 4
208000032839 leukemia Diseases 0.000 description 4
201000002250 liver carcinoma Diseases 0.000 description 4
229960004857 mitomycin Drugs 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 3
239000006145 Eagle's minimal essential medium Substances 0.000 description 3
102000014150 Interferons Human genes 0.000 description 3
108010050904 Interferons Proteins 0.000 description 3
102000008072 Lymphokines Human genes 0.000 description 3
108010074338 Lymphokines Proteins 0.000 description 3
229920002684 Sepharose Polymers 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000003795 desorption Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000002523 gelfiltration Methods 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
239000011148 porous material Substances 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
238000005185 salting out Methods 0.000 description 3
201000000849 skin cancer Diseases 0.000 description 3
201000008261 skin carcinoma Diseases 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
241000894007 species Species 0.000 description 3
238000005406 washing Methods 0.000 description 3
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
238000011729 BALB/c nude mouse Methods 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
241000699660 Mus musculus Species 0.000 description 2
206010028851 Necrosis Diseases 0.000 description 2
201000000582 Retinoblastoma Diseases 0.000 description 2
206010039491 Sarcoma Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
230000024932 T cell mediated immunity Effects 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
238000011047 acute toxicity test Methods 0.000 description 2
230000002730 additional effect Effects 0.000 description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
229910052921 ammonium sulfate Inorganic materials 0.000 description 2
235000011130 ammonium sulphate Nutrition 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
238000003556 assay Methods 0.000 description 2
230000003416 augmentation Effects 0.000 description 2
201000009613 breast lymphoma Diseases 0.000 description 2
239000000872 buffer Substances 0.000 description 2
244000309466 calf Species 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
239000002799 interferon inducing agent Substances 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
239000007928 intraperitoneal injection Substances 0.000 description 2
230000001678 irradiating effect Effects 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
229940057995 liquid paraffin Drugs 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
230000017074 necrotic cell death Effects 0.000 description 2
229940067107 phenylethyl alcohol Drugs 0.000 description 2
-1 phthalate ester Chemical class 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002203 pretreatment Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
229940099259 vaseline Drugs 0.000 description 2
241000894006 Bacteria Species 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
241000009328 Perro Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
239000013543 active substance Substances 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
210000001691 amnion Anatomy 0.000 description 1
230000003190 augmentative effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
239000012050 conventional carrier Substances 0.000 description 1
238000012136 culture method Methods 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
230000001861 immunosuppressant effect Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000005229 liver cell Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
210000001161 mammalian embryo Anatomy 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
239000011369 resultant mixture Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000002226 simultaneous effect Effects 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
102000003390 tumor necrosis factor Human genes 0.000 description 1
201000005112 urinary bladder cancer Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
230000009385 viral infection Effects 0.000 description 1

Landscapes

Preparation Of Compounds By Using Micro-Organisms (AREA)

CA000408532A 1981-07-31 1982-07-30 Procede de production de facteur de lyse de cellules cibles et utilisation Expired CA1213544A (fr)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
JP120459/1981		1981-07-31
JP56120459A JPS5821621A (ja)	1981-07-31	1981-07-31	ヒトツモア・ネクロシス・ファクタ−を含有する悪性腫瘍治療剤
JP56187626A JPS5889195A (ja)	1981-11-21	1981-11-21	標的細胞障害性因子の製造方法
JP187626/1981		1981-11-21
JP56187627A JPH0764744B2 (ja)	1981-11-21	1981-11-21	標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤
JP187627/1981		1981-11-21
JP205115/1981		1981-12-21
JP56205115A JPS6011890B2 (ja)	1981-12-21	1981-12-21	ツモアネクロシスフアクタ−の製造方法

Publications (1)

Publication Number	Publication Date
CA1213544A true CA1213544A (fr)	1986-11-04

Family

ID=27470687

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000408532A Expired CA1213544A (fr)	1981-07-31	1982-07-30	Procede de production de facteur de lyse de cellules cibles et utilisation

Country Status (1)

Country	Link
CA (1)	CA1213544A (fr)

1982
- 1982-07-30 CA CA000408532A patent/CA1213544A/fr not_active Expired

Legal Events

Date	Code	Title	Description
2003-11-04	MKEX	Expiry

Publication	Publication Date	Title
US4495282A (en)	1985-01-22	Process for producing target cell lysis factor and uses therewith
US5597901A (en)	1997-01-28	Homogeneous human interleukin 2
US4789658A (en)	1988-12-06	Immunoprophylactic and immunotherapeutic agents
RU2107728C1 (ru)	1998-03-27	Способ получения человеческого иммунного интерферона
US5362490A (en)	1994-11-08	Human myelomonocyte interferon-gamma, and process for preparation and use thereof
US4683199A (en)	1987-07-28	Interleukin-2 dependent cytotoxic T-cell clones
US4758549A (en)	1988-07-19	Lymphokine, monoclonal antibody specific to the lymphokine and their production and uses
US5002878A (en)	1991-03-26	Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses
JPS6011890B2 (ja)	1985-03-28	ツモアネクロシスフアクタ−の製造方法
JP2926409B2 (ja)	1999-07-28	癌転移抑制因子の製造方法
EP0216605B1 (fr)	1992-07-22	Lymphokine, sa production et ses applications
JPS6019720A (ja)	1985-01-31	ヒト内来性癌制御因子およびその製造法
JP2532025B2 (ja)	1996-09-11	新リンホカインｉｉｉを有効成分とする抗腫瘍作用を有するリンホカインの活性増強剤
JPH0764744B2 (ja)	1995-07-12	標的細胞障害性因子とヒトインタ−フェロンとを有効成分として含有する悪性腫瘍治療剤
JP2518634B2 (ja)	1996-07-24	ヒトツモア・ネクロシス・フアクタ−の製造方法
KR870001433B1 (ko)	1987-08-06	적상적혈구(的狀赤血球) 붕괴인자의 제조 방법
JP2632849B2 (ja)	1997-07-23	γ―インターフェロンの製造方法
JP2518635B2 (ja)	1996-07-24	ヒトツモア・ネクロシス・フアクタ−
Igarashi et al.	1982	Induction of the differentiation of memory T killer cells with factors released from macrophage-like cell lines
Grönvik et al.	1982	A stable TCGF-producing T cell hybridoma and its thioguanine-resistant variant suitable as a tool for the construction of new functional T hybridomas
JP2566761B2 (ja)	1996-12-25	骨髄単球系細胞
JPH0446928B2 (fr)	1992-07-31
JPS61115028A (ja)	1986-06-02	抗腫瘍効果増強剤
JPS5889195A (ja)	1983-05-27	標的細胞障害性因子の製造方法
JPH0527640B2 (fr)	1993-04-21